Updated Data from JP28927 Study of Alectinib in ALK plus NSCLC Patients with or without History of ALK Inhibitor Treatment

被引：0
|
作者：
Hotta, Katsuyuki [1 ]
Hida, Toyoaki [2 ]
Nakagawa, Kazuhiko [3 ]
Seto, Takashi [4 ]
Satouchi, Miyako [5 ]
Nishio, Makoto [6 ]
Murakami, Haruyasu [7 ]
Ohe, Yuichiro [8 ]
Takeda, Koji [9 ]
Yoshimoto, Takuya [10 ]
Tanaka, Tomohiro [10 ]
Tamura, Tomohide [11 ]
机构：
[1] Okayama Univ Hosp, Okayama, Japan
[2] Aichi Canc Ctr, Nagoya, Aichi 464, Japan
[3] Kinki Univ, Fac Med, Osaka, Japan
[4] Kyushu Natl Canc Ctr, Fukuoka, Japan
[5] Hyogo Canc Ctr, Akashi, Hyogo, Japan
[6] Jfcr, Canc Inst Hosp, Tokyo, Japan
[7] Shizuoka Canc Ctr, Shizuoka, Japan
[8] Natl Canc Ctr, Tokyo, Japan
[9] Osaka City Gen Hosp, Osaka, Japan
[10] Chugai Pharmaceut Co Ltd, Tokyo, Japan
[11] St LukeS Int Hosp, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
Alectinib; ALK plus NSCLC; ALK Inhibitor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-020
引用
收藏
页码：S648 / S648
页数：1
相关论文
共 50 条
  • [1] Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK plus non-small-cell lung cancer with or without prior crizotinib therapy
    Hida, Toyoaki
    Nakagawa, Kazuhiko
    Seto, Takashi
    Satouchi, Miyako
    Nishio, Makoto
    Hotta, Katsuyuki
    Takahashi, Toshiaki
    Ohe, Yuichiro
    Takeda, Koji
    Tatsuno, Masahiro
    Asakawa, Takashi
    Shimada, Tadashi
    Tanaka, Tomohiro
    Tamura, Tomohide
    CANCER SCIENCE, 2016, 107 (11) : 1642 - 1646
  • [2] Updated Efficacy/Safety Data From the Phase 2 NP28761 Study of Alectinib in ALK plus NSCLC
    Shaw, Alice
    West, Howard
    Socinski, Mark A.
    Ou, Ignatius
    Gandhi, Leena
    Gadgeel, Shirish
    Belani, Chandra P.
    Shirai, Keisuke
    Bazhenova, Lyudmila
    Santos, Edgardo
    Riely, Gregory J.
    Chiappori, Alberto
    Cetnar, Jeremy
    Mekhail, Tarek
    Chao, Bo
    Borghaei, Hossein
    Gold, Kathryn A.
    Johannsdottir, Hrefna
    Ruf, Thorsten
    Boisserie, Frederic
    Henschel, Volkmar
    Zeaiter, Ali
    Camidge, Ross
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S237 - S238
  • [3] Targeted adjuvant: First Data on Alectinib in Patients with operable ALK plus NSCLC
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (05)
  • [4] Updated Data of a Phase 1/2 Study (AF-001JP) of Alectinib, a CNS-Penetrant, Highly Selective ALK Inhibitor in ALK-rearranged Advanced NSCLC
    Tamura, T.
    Seto, T.
    Nakagawa, K.
    Maemondo, M.
    Inoue, A.
    Hida, T.
    Yoshioka, H.
    Harada, M.
    Ohe, Y.
    Nogami, N.
    Murakami, H.
    Takeuchi, K.
    Asakawa, T.
    Kikuchi, K.
    Tanaka, T.
    Nishio, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S6 - S6
  • [5] Final Result of Phase I/II Study (AF-001JP) of Alectinib, a Selective CNS-Active ALK Inhibitor, in ALK plus NSCLC Patients (Pts)
    Nishio, M.
    Kiura, K.
    Seto, T.
    Nakagawa, K.
    Maemondo, M.
    Inoue, A.
    Hida, T.
    Yoshioka, H.
    Harada, M.
    Ohe, Y.
    Nogami, N.
    Murakami, H.
    Takeuchi, K.
    Inamura, S.
    Kuriki, H.
    Shimada, T.
    Tamura, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1757 - S1757
  • [6] The Optimal ALK inhibitor in Advanced ALK-Positive NSCLC Patients: An Indirect Comparison Between Brigatinib and Alectinib
    Chen, G.
    Zhang, Y.
    Zhou, H.
    Zhao, S.
    Liu, J.
    Hong, S.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1056 - S1056
  • [7] Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK plus NSCLC
    Ou, Sai-Hong Ignatius
    Gandhi, Leena
    Shaw, Alice
    Govindan, Ramaswamy
    Socinski, Mark
    Camidge, D. Ross
    De Petris, Luigi
    Kim, Dong-Wan
    Chiappori, Alberto
    Moro-Sibilot, Denis
    Duruisseaux, Michael
    Crino, Lucio
    De Pas, Tommaso
    Dansin, Eric
    Tessmer, Antje
    Yang, James Chih-Hsin
    Han, Ji-Youn
    Bordogna, Walter
    Golding, Sophie
    Zeaiter, Ali
    Gadgeel, Shirish
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S377 - S377
  • [8] ALKTERNATE: A Pilot Study Alternating Lorlatinib with Crizotinib in Patients with ALK plus NSCLC and ALK-inhibitor Resistance
    Itchins, M.
    Liang, S.
    Brown, C.
    Barnes, T.
    Marx, G.
    Chin, V.
    Kao, S.
    Yip, P. Y.
    Mersiades, A. J.
    Nagrial, A.
    Bray, V.
    Peters, G.
    Parakh, S.
    John, T.
    Li, M.
    Li, B. T.
    McKay, M.
    Molloy, M.
    O'Byrne, K.
    Lee, C.
    Gill, A.
    Solomon, B. J.
    Pavlakis, N.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S351 - S352
  • [9] Phase 2 Study of Ceritinib in Patients with ALK plus NSCLC with Prior Alectinib Treatment in Japan: ASCEND-9
    Horinouchi, H.
    Maemondo, M.
    Hida, T.
    Takeda, M.
    Hotta, K.
    Hirai, F.
    Kim, Y.
    Matsumoto, S.
    Mitsudomi, T.
    Seto, T.
    Moizumi, S.
    Tokushige, K.
    Hatano, B.
    Nishio, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1951 - S1952
  • [10] Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naive ALK fusion positive non-small cell lung cancer (ALK plus NSCLC).
    Takiguchi, Yuichi
    Hida, Toyoaki
    Nokihara, Hiroshi
    Kondo, Masashi
    Kim, Young Hak
    Azuma, Koichi
    Seto, Takashi
    Nishio, Makoto
    Yoshioka, Hiroshige
    Imamura, Fumio
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Kuriki, Hiroshi
    Inagaki, Naohito
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345